posted
went to a late lunch and this chit.. sucks.. im hoping it will pop from this.. huge vol on nothing but selling, just insane how toxic this is looking. mm's have a lot of shares on their hands here, we'll see what happens. no doubt Zeker, im scared too, lol.. i do not like this selling this low.. at least the vol is there.. geesh..
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
Industry : BiotechnologyEmployees : 10Exchange : OTC BB
Debt/Equity Ratio 3.21 Gross Margin NA Net Profit Margin -17153.85% Total Shares Outstanding 1.1 Bil Market Capitalization 54.74 Mil Earnings/Share -0.21 StockScouter Rating NA
Stem Cell Innovations, Inc. has a business relating to the use of the Company's C3A human liver cell line in the field of drug discovery and toxicology testing. The Company has not yet developed any substantial market for its primary products. Stem Cell Innovations' principal revenues have been contract research and testing and consulting services for other companies, which have historically been minimal.
-------------------- Timing, not image, is EVERYTHING Posts: 26 | From: charlotte, nc | Registered: Aug 2005
| IP: Logged |
posted
Wow, that was un-expected. But I must say I like it even more. We got a RHOI on our hands?
-------------------- Do not trade on my advise, if I have any to give, lol. Up 127% since joined the website. Posts: 205 | From: New England (MA) | Registered: Jan 2007
| IP: Logged |
posted
whew, what a relief so far.. NITE backing off, it still has to finish strong to mean anything, but i feel a little better today..
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
posted
still selling at these low levels, but tons of buying.. just crazy volume for a stock at this price, maybe somethings up? who knows..
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
posted
freaking red close, lmao.. unreal.. everlasting POS.
wait for them to gap it pre market i guess, thinking that is mm's strategy to deal with this toxic selling.. almost 13 mill in vol.. huge selling and huge buying.. dang
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
posted
Editorial: Stem cell dollars flow But grant process is needlessly shrouded Published 12:00 am PST Monday, February 12, 2007 Story appeared in EDITORIALS section, Page B4
Print | E-Mail | Comments
California's stem cell research institute has received little attention of late, and agency officials probably prefer it that way. But while the media have been off covering sex scandals involving mayors and astronauts, the Institute for Regenerative Medicine has been quietly preparing, for the first time in its two-year history, to dispense millions of public dollars for embryonic stem cell research.
This week, on Thursday and Friday, the institute's oversight committee will meet in San Francisco to decide on roughly $24 million in grants for new stem cell researchers with innovative ideas. While that may be pocket change compared with the $3 billion that voters authorized when they endorsed Proposition 71 in 2004, this initial research funding is historic, and other grants totaling about $100 million will soon follow this year.
Taxpayers curious about how their money will be spent can go to the institute's Web site -- www.cirm.ca.gov/publicsummaries/PublicList.html -- to see the 30 scientific proposals recommended for funding. The site also includes 200 other projects that didn't make the cut, with summaries and scientific assessments -- some of them surprisingly blunt -- about each proposal.
Once the institute's oversight board makes its final decision this week, it will identify the names and affiliations of scientists receiving grants but not those who didn't receive funding. Some watchdog groups say the oversight board should disclose all names, but institute leaders say that might embarrass researchers and discourage them from applying for grants. They also note the National Institutes of Health don't disclose such information.
We have some questions about the stem cell institute's rationale, but our bigger concern is its procedures for reviewing proposals and selecting projects to fund.
Scientists from outside states do much of this review work, and are not required to publicly disclose their potential conflicts of interest. Undoubtedly, some of those scientists have outside consulting work, or personal relationships with researchers seeking funding, that could affect their grant decisions. Yet under the institute's shrouded procedures, it is impossible for anyone -- including researchers applying for grants -- to be assured that grant reviewers are recusing themselves at the proper times.
This lack of public disclosure is the single most glaring problem with the Institute for Regenerative Medicine. While it is momentous that California is now on the leading edge of financing embryonic stem cell research, the institute still hasn't adopted a transparent procedure for policing potential conflicts. Lawmakers, in this session of the Legislature, need to correct that.
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
February 12, 2007, 1:34PM EST U.S., U.K. to promote stem cell research By RYAN J. FOLEY
Story Tools order a reprint digg this save to del.icio.us MADISON, Wis.
Leaders of national embryonic stem cell banks in the United States and the United Kingdom met here, in the birthplace of the field, on Monday and pledged to work together to promote research.
Representatives of the two banks said they were discussing ways to more efficiently distribute each other's cells to scientists and new standards to improve the quality of cells available.
The discussion came as Wisconsin Gov. Jim Doyle and leaders of the National Stem Cell Bank in Madison hosted a U.K. delegation that included the director of the U.K. Stem Cell Bank and chairman of the U.K. oversight committee on stem cell research.
At a news conference, the leaders said they hoped the efforts were the beginning of a long partnership between the banks. While stem cell research is still in its early stages, scientists believe it may eventually lead to treatment and perhaps cures for diseases such as Parkinson's and juvenile diabetes.
"This is not about one side, one state or one country winning and one losing," Doyle said. "This is about a huge area of scientific research that is expanding rapidly around the world, that we in Wisconsin happen to find ourselves in a leadership position."
The government-funded U.K. bank opened in 2004 as a repository for stem cells derived from embryos and adults. Its American counterpart was created the following year at WiCell Research Institute, a nonprofit connected to the University of Wisconsin, under a federal contract.
The U.S. bank houses and distributes 13 of the 21 embryonic stem cell lines that can be used in federally funded research under President Bush's policy limiting support to lines created before 2001. Wisconsin researcher James Thomson isolated the first of those lines in 1998.
Stem cells are created in the first days after conception. Because they go on to form the body's tissues and cells, scientists say they could unlock the mystery of many diseases and one day lead to cures.
But some people oppose the research because days-old embryos -- usually leftover from fertility treatments -- are destroyed in the effort to isolate the cells.
The two banks said they would discuss international standards for how cells are ethically derived from human embryos and maintained.
"Our main focuses are very similar: we want to promote the research and the development of potential therapies in the future," said Glyn Stacey, director of the U.K. bank. "These are the kinds of issues we're talking about and trying to make appropriate cell lines available to researchers and for clinical trials as well."
Carl Gulbrandsen, president of WiCell, said the two would discuss joint distribution of each other's cell lines. His group has already reached distribution agreements with some overseas companies.
"Shipping stem cell lines overseas is no easy task, hoping they arrive, they are healthy and can be used," he said.
But even as the banks work together, U.K. and American scientists will be operating under very different restrictions. U.K. researchers are allowed to clone embryos to extract stem cells and can qualify for government funding for such work.
In the U.S., some states have outlawed therapeutic cloning. And while the new Democratic Congress is trying to loosen Bush's restrictions, no federal money is now available for cloning embryos or new stem cell lines.
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
Stem Cell Innovations to Present Data at the Stem Cells World Congress That PluriCells(TM) Can Produce Cells Important in Cardiovascular Disease 8:00a ET February 13, 2007 (Business Wire)
Stem Cell Innovations, Inc., or "SCI" (OTCBB: SCLL) announced today that James H. Kelly, Ph.D, Chief Executive Officer of Stem Cell Innovations (SCI), Inc. will present data at the Stem Cells World Congress in San Diego describing further characterization and extension of SCI's PluriCell(TM) stem cell system. The Congress draws together experts from academia and industry to discuss progress in the stem cell arena. In particular, Dr. Kelly will describe the ability of PluriCells(TM) to become endothelial cells, the cells that line the arteries and which are central players in cardiovascular disease. Normal adults have few circulating endothelial precursors in their blood but increased levels have been shown in conditions associated with myocardial infarction and stroke. PluriCells(TM) can provide both a drug discovery platform and also a potential cell therapy for use in these conditions.
"We are excited by the data demonstrating the important role PluriCells(TM) may play in cardiovascular disease," Kelly said. "The recent issuance of our patent on human pluripotent cells derived from primordial germ cells gives us a dominant intellectual property position in one of the two known types of fully pluripotent stem cells. The development of the endothelial cells, in combination with the other cell types we have already demonstrated, increases our ability to exploit this powerful system for both drug discovery and cell therapy."
SCI is developing PluriCells(TM), a new human stem cell technology derived from primordial germ cells of fetal tissue. PluriCells(TM) are distinct from embryonic stem (ES) cells. Primordial germ cells are one of only two types of cells known to be able to produce all of the more than 200 cell types found in the human body. The primordial germ cells are the cells that eventually produce the sperm and the egg, passing the genome along to the next generation. Stem cell cultures generated from these cells are believed to have tremendous promise in advancing drug discovery and cell-based therapies for some of our most intractable health problems, such as neurodegenerative and cardiovascular disease.
About Stem Cell Innovations, Inc.
SCI is a cell biology company with facilities in Scotch Plains, NJ, Houston, TX and in Leiden, the Netherlands. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells(TM), have the potential to aid in drug discovery, toxicology, and cell therapy.
Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell(TM) technology greatly expands the Company's currently marketed C3A human liver cell-based toxicology offerings.
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
posted
"James Kelly" <jkelly*amphioxus.com> Add to Address Book Add Mobile Alert Subject: Stem Cell Innovations Date: feb. 06, 2007 Mr....
At the time of the merger that formed the company (Feb 14, 2006), we did a financing for shares at $0.03. The one year holding period for those shares expires on Feb 14. This information is in our SEC filings. While I have no real ability to know who exactly is selling, I presume that the anniversary of that date accounts for the recent increase in our volume.
I just wanted to assure you that there are no problems at the company. It is simply people who got in at a price and are now liquidating their position to take their money off the table. I expect that there will be more of this over the next weeks. It has no relation to our long term prospects.
posted
Just when you think the bottom might be here I read your post. I have been on the sidelines with the trigger finger ready but I will hold off again I guess. I appreciate the info. cactus. I thought this was just about to go but with the dumping it is hard to foresee the price in the short term. It is so oversold!!
Posts: 316 | Registered: Oct 2005
| IP: Logged |
posted
Anyone think they might come out with good news to get the pps up for those selling their now tradeable shares?
Posts: 316 | Registered: Oct 2005
| IP: Logged |
posted
a lot of the selling has been due to people anticipating big selling, that may not be the case.. i still think selling dries up soon, as crazy as that sounds i guess, lol
Posts: 6397 | Registered: Jan 2006
| IP: Logged |
posted
technicals setting up for big rebound, buyers are coming back the last 3 days...last weeks sell volume was insane, appears majority of sells came from a few individuals/groups,rsi was driven way down
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Confused]](confused.gif)
![[Mad]](mad.gif)
![[Eek!]](eek.gif)
